

PUBLIC COPY

RECEIVED
OPPT CBIC

2019 MAR 12 PM 11:44

March 11, 2019

Via Federal Express

CBIC Control Number

381651~S

Document Processing Center (Mail Code 7407M)
Room 6428
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
1201 Constitution Ave., NW
Washington, DC 20004

Dear 8(e) Coordinator:

Test Substance:

8EHQ-18-21340 and 8EHQ-19-21623

Generic Name: Chlorofluorocarbon

This letter is to inform you of the results of a fourteen-day inhalation toxicity study with the above-referenced test substance in rabbits. This information is submitted in accordance with current guidance issued by EPA indicating EPA's interpretation of Section 8(e) of the Toxic Substances Control Act or, where it is not clear that reporting criteria have been met, because it is information in which EPA may have an interest.

The objective of this study was to evaluate the potential toxic effects of the test substance when administered to New Zealand White rabbits via whole-body inhalation for 2 weeks. The test substance was administered to groups of 10 New Zealand White Rabbits (5 animals/sex) via whole-body inhalation for 6 hours per day, for 5 days per week, for 2 weeks (minimum of 10 exposures) at target exposure concentrations of 0, 35, 125, and 350 ppm for Groups 1, 2, 3, and 4, respectively. Achieved mean analyzed exposure concentrations in the 35, 125, and 350 ppm groups were 36, 128, and 348 ppm, respectively.

The following parameters and end points were evaluated in this study: clinical signs, body weights, body weight gains, food consumption, clinical pathology parameters (hematology, coagulation, and serum chemistry), gross necropsy findings, organ weights, and histopathologic examinations.

All animals survived until the scheduled necropsy. There were no test substance-related clinical observations or effects on food consumption, hematology, or coagulation. There were no test substance-related macroscopic findings.

Test substance-related, nonadverse lower body weight gains were noted in the 125 and 350 ppm group males from Day 7 to 11.

Test substance-related, nonadverse effects on serum chemistry were noted in the 350 ppm group males and females and included higher alanine aminotransferase, aspartate aminotransferase (males only), and triglycerides (males only).

Test substance-related, nonadverse changes in organ weights were limited to higher liver weights in the 125 and 350 ppm group males and females.

PUBLIC COPY

Test substance-related microscopic findings included adverse cardiomyocyte degeneration/necrosis in the heart for 1 female in the 350 ppm group and a nonadverse finding of myofiber degeneration/necrosis in the skeletal muscle for the same female as well as 1 male in the 350 ppm group.

Based on the results of this study, whole body inhalation of the test substance to New Zealand White rabbits at exposure levels of 35, 125, and 350 ppm for 6 hours per day, 5 days per week, for 2 weeks (minimum of 10 exposures) resulted in an adverse microscopic finding of cardiomyocyte degeneration/necrosis in the heart for a single female in the 350 ppm group. Therefore, the no-observed-adverse-effect concentration (NOAEC) was considered to be 350 ppm for males and 125 ppm for females.

I hereby certify to the best of my knowledge and belief that all information entered on this form is complete and accurate.

I further certify that, pursuant to 15 U.S.C. § 2613(c), for all claims for confidentiality made with this submission, all information submitted to substantiate such claims is true and correct, and that it is true and correct that

- (i) My company has taken reasonable measures to protect the confidentiality of the information;
- (ii) I have determined that the information is not required to be disclosed or otherwise made available to the public under any other Federal law;
- (iii) I have a reasonable basis to conclude that disclosure of the information is likely to cause substantial harm to the competitive position of my company; and
- (iv) I have a reasonable basis to believe that the information is not readily discoverable through reverse engineering.

Any knowing and willful misrepresentation is subject to criminal penalty pursuant to 18 U.S.C. § 1001.

Substantiation of our claim of confidentiality is included herewith as **Attachment 1**. Please contact me if you have any questions about this submission or need further clarification.

Sincerely,

PUBLIC COPY

Attachment 1

Entire Substantiation Claimed as Confidential Business Information